Skip to main contentSkip to search and navigation

UEF eREPOSITORY

    • English
    • suomi
  • English 
    • English
    • suomi
  • Login
View Item 
  •   Home
  • Artikkelit
  • Terveystieteiden tiedekunta
  • View Item
  •   Home
  • Artikkelit
  • Terveystieteiden tiedekunta
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Novel in vitro method reveals drugs that inhibit solute transporter alpha/beta

Thumbnail
Files
Article (1.134Mb)
Self archived version
final draft
Date
2019
Author(s)
Malinen, Melina M
Kauttonen, Antti
Beaudoin, James J
Sjöstedt, Noora
Honkakoski, Paavo
Brouwer, Kim LR
Unique identifier
10.1021/acs.molpharmaceut.8b00966
Metadata
Show full item record
More information
Research Database SoleCris

Self-archived article

Citation
Malinen, Melina M. Kauttonen, Antti. Beaudoin, James J. Sjöstedt, Noora. Honkakoski, Paavo. Brouwer, Kim LR. (2019). Novel in vitro method reveals drugs that inhibit solute transporter alpha/beta.  Molecular Pharmaceutics, 16 (1) , 238-246. 10.1021/acs.molpharmaceut.8b00966.
Rights
© American Chemical Society
Licensed under
All rights reserved
Abstract

Drug interactions with the organic solute transporter alpha/beta (OSTα/β) are understudied even though OSTα/β is an important transporter that is expressed in multiple human tissues including the intestine, kidneys, and liver. In this study, an in vitro method to identify novel OSTα/β inhibitors was first developed using OSTα/β-overexpressing Flp-In 293 cells. Incubation conditions were optimized using previously reported OSTα/β inhibitors. A method including a 10 min preincubation step with the test compound was used to screen for OSTα/β inhibition by 77 structurally diverse compounds and fixed-dose combinations. Seven compounds and one fixed-dose combination (100 μM final concentration) inhibited OSTα/β-mediated dehydroepiandrosterone sulfate (DHEAS) uptake by >25%. Concentration-dependent OSTα/β inhibition was evaluated for all putative inhibitors (atorvastatin, ethinylestradiol, fidaxomicin, glycochenodeoxycholate, norgestimate, troglitazone, and troglitazone sulfate). Ethinylestradiol, fidaxomicin, and troglitazone sulfate yielded a clear concentration–inhibition response with IC50 values <200 μM. Among all tested compounds, there was no clear association between physicochemical properties, the severity of hepatotoxicity, and the degree of OSTα/β inhibition. This study utilized a novel in vitro method to identify OSTα/β inhibitors and, for the first time, provided IC50 values for OSTα/β inhibition. These data provide evidence that several drugs, some of which are associated with cholestatic drug-induced liver injury, may impair the function of the OSTα/β transporter.

Subjects
basolateral efflux   bile acid   cholestasis   drug-induced liver injury   inhibition   SLC51A/B   
URI
https://erepo.uef.fi/handle/123456789/7407
Link to the original item
http://dx.doi.org/10.1021/acs.molpharmaceut.8b00966
Publisher
American Chemical Society (ACS)
Collections
  • Terveystieteiden tiedekunta [1330]
University of Eastern Finland
OpenAccess
eRepo
erepo@uef.fi
UEF Open Science
Accessibility in eRepo
Service provided by
the University of Eastern Finland Library
Library web pages
Twitter
Facebook
Youtube
Library blog
 sitemap
Search

Browse

All of the ArchiveResource types & CollectionsBy Issue DateAuthorsTitlesSubjectsFacultyDepartmentFull organizationSeriesMain subjectThis CollectionBy Issue DateAuthorsTitlesSubjectsFacultyDepartmentFull organizationSeriesMain subject

My Account

Login
University of Eastern Finland
OpenAccess
eRepo
erepo@uef.fi
UEF Open Science
Accessibility in eRepo
Service provided by
the University of Eastern Finland Library
Library web pages
Twitter
Facebook
Youtube
Library blog
 sitemap